Higher levels of stromal TILs were strongly associated with better prognosis in early-stage triple-negative breast cancer and HER2-positive breast cancer and better clinical outcomes in patients treated with adjuvant, neoadjuvant chemotherapy, or PD-1 inhibitors. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.